<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:GILD="http://gilead.com/20240211">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_GILD_gilead.com_20240211 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20240211_20240211 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000882095 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:AmendmentFlag" id="ixv-319">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:EntityCentralIndexKey" id="ixv-320">0000882095</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-02-11" id="xdx2ixbrl0017" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gild-20240211.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-02-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-11</xbrli:startDate>
        <xbrli:endDate>2024-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"></p>


<p style="border-bottom: Black 3pt solid; margin: 0">&#160;</p>

<p style="border-bottom: Black 1pt solid; margin: 0pt; padding-top: 0pt; padding-bottom: 2pt"></p>


<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>UNITED STATES&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.55pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 2.6pt; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 2.6pt; text-align: center"><b></b></p>



<p style="margin: 0">&#160;</p>
<p style="margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 10pt">____________________________</span></p>
<p style="margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 2.6pt; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 2.6pt; text-align: center"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>FORM <span id="xdx_904_edei--DocumentType_c20240211__20240211_zSE48PpgnpPc"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:DocumentType" id="ixv-341">8-K</ix:nonNumeric></span></b></p>



<p style="margin: 0"></p>
<p style="margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 10pt">____________________________</span></p>
<p style="margin: 0">&#160;</p>


<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.1pt 0pt 176.35pt; text-align: center; text-indent: -0.05pt"><b>Pursuant
to Section 13 or 15(d) of&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.1pt 0pt 176.35pt; text-align: center; text-indent: -0.05pt"><b>The
Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.1pt 0pt 176.35pt; text-align: center; text-indent: -0.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>DATE OF REPORT (DATE OF EARLIEST
EVENT REPORTED): <span id="xdx_906_edei--DocumentPeriodEndDate_c20240211__20240211_zUzkl29B4Wsb"><ix:nonNumeric contextRef="AsOf2024-02-11" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-342">FEBRUARY 11, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center">&#160;&#160;</p>
<p style="margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 10pt">____________________________</span></p>
<p style="margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b><span id="xdx_90A_edei--EntityRegistrantName_c20240211__20240211_zIyLwCJq7yr7"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:EntityRegistrantName" id="ixv-343">GILEAD SCIENCES, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.6pt; text-align: center">(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.6pt; text-align: center">&#160;</p>



<p style="margin: 0"></p>
<p style="margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 10pt">____________________________</span></p>
<p style="margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.6pt; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center; width: 33%"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20240211__20240211_z2kY3pUSbht8"><ix:nonNumeric contextRef="AsOf2024-02-11" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-344">Delaware</ix:nonNumeric></span></b></td>
    <td style="font-size: 10pt; text-align: center; width: 34%"><b><span id="xdx_904_edei--EntityFileNumber_c20240211__20240211_zAdPjKO9OyF"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:EntityFileNumber" id="ixv-345">0-19731</ix:nonNumeric></span></b></td>
    <td style="font-size: 10pt; text-align: center; width: 33%"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20240211__20240211_zIr3xQgneHi1"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:EntityTaxIdentificationNumber" id="ixv-346">94-3047598</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)&#160;</p></td>
    <td style="font-size: 10pt; text-align: center">(Commission File No.)</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20240211__20240211_zHbKMUlhEJ64"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:EntityAddressAddressLine1" id="ixv-347">333 LAKESIDE DRIVE</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressCityOrTown_c20240211__20240211_zhgTUsLJf2n8"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:EntityAddressCityOrTown" id="ixv-348">FOSTER CITY</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20240211__20240211_z0bZQtAejslc"><span style="-sec-ix-hidden: xdx2ixbrl0017">CALIFORNIA</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center">(Address of principal executive
offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b><span id="xdx_90C_edei--EntityAddressPostalZipCode_c20240211__20240211_zf0X4bOXVBQ2"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:EntityAddressPostalZipCode" id="ixv-349">94404</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center">(Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b><span id="xdx_905_edei--CityAreaCode_c20240211__20240211_zpVnUsAMyRXd"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:CityAreaCode" id="ixv-350">(650)</ix:nonNumeric></span> <span id="xdx_908_edei--LocalPhoneNumber_c20240211__20240211_z33YRiPXXUUb"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:LocalPhoneNumber" id="ixv-351">574-3000</ix:nonNumeric></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.55pt; text-align: center">(Registrant&#8217;s telephone number,
including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.55pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b>Not Applicable&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.55pt; text-align: center">(Former name or former address,
if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.55pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90E_edei--WrittenCommunications_c20240211__20240211_ztivGFbXqOVi"><ix:nonNumeric contextRef="AsOf2024-02-11" format="ixt:booleanfalse" name="dei:WrittenCommunications" id="ixv-352">&#9744;</ix:nonNumeric></span>&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90C_edei--SolicitingMaterial_c20240211__20240211_zcJtNwHB6j19"><ix:nonNumeric contextRef="AsOf2024-02-11" format="ixt:booleanfalse" name="dei:SolicitingMaterial" id="ixv-353">&#9744;</ix:nonNumeric></span>&#160;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_900_edei--PreCommencementTenderOffer_c20240211__20240211_zGPEa6aCPC69"><ix:nonNumeric contextRef="AsOf2024-02-11" format="ixt:booleantrue" name="dei:PreCommencementTenderOffer" id="ixv-354">&#9746;</ix:nonNumeric></span>&#160;
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20240211__20240211_zsK3qOoLF0Rj"><ix:nonNumeric contextRef="AsOf2024-02-11" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer" id="ixv-355">&#9744;</ix:nonNumeric></span>&#160;
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 1pt; border: black 1pt solid; font-size: 10pt; text-align: center; width: 33%; padding-bottom: 1pt">Title of each class</td>
    <td style="padding-top: 1pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; width: 34%; padding-bottom: 1pt">Trading Symbol(s)</td>
    <td style="padding-top: 1pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-bottom: 1pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Name of each exchange on which&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">registered&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center; padding-bottom: 1pt"><b><span id="xdx_903_edei--Security12bTitle_c20240211__20240211_zjZuoteGbzol"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:Security12bTitle" id="ixv-356">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></b></td>
    <td style="padding-top: 1pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-bottom: 1pt"><b><span id="xdx_906_edei--TradingSymbol_c20240211__20240211_zFgenRZrlKL8"><ix:nonNumeric contextRef="AsOf2024-02-11" name="dei:TradingSymbol" id="ixv-357">GILD</ix:nonNumeric></span></b></td>
    <td style="padding-top: 1pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-bottom: 1pt"><b><span id="xdx_905_edei--SecurityExchangeName_c20240211__20240211_z56svTGlaCf3"><ix:nonNumeric contextRef="AsOf2024-02-11" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-358">The Nasdaq Global Select Market</ix:nonNumeric></span></b></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR &#167;240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20240211__20240211_zF72VFOLsgE2"><ix:nonNumeric contextRef="AsOf2024-02-11" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="ixv-359">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<p style="margin: 0">&#160;&#160;</p>

<p style="border-bottom: Black 3pt solid; margin: 0pt; padding-top: 0pt; padding-bottom: 2pt"></p>

<p style="margin: 0">&#160;&#160;&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 12%; font-size: 10pt"><b>Item 1.01</b></td>
    <td style="width: 88%; font-size: 10pt; text-align: justify"><b>Entry into a Material Definitive Agreement</b></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 11, 2024, Gilead Sciences, Inc., a
Delaware corporation (&#8220;<span style="text-decoration: underline">Parent</span>&#8221; or &#8220;<span style="text-decoration: underline">Gilead</span>&#8221;),
entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;), among
Parent, CymaBay Therapeutics, Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;),
and Pacific Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Merger Agreement, and upon the
terms and subject to the conditions thereof, Purchaser will commence a tender offer (the &#8220;<span style="text-decoration: underline">Offer</span>&#8221;),
to purchase all of the issued and outstanding shares (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;) of common
stock, par value $0.0001 per share, of the Company, other than any Shares held immediately prior to the effective time of the Merger by
the Company (or held in the Company&#8217;s treasury) and any Shares held immediately prior to the effective time of the Merger by Parent,
Purchaser or any other direct or indirect wholly owned subsidiary of Parent at a price of $32.50 per Share (the &#8220;<span style="text-decoration: underline">Offer
Price</span>&#8221;), net to the seller in cash, without interest and subject to any required withholding of taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Offer will initially remain open for a minimum
of 20 business days from the date of commencement of the Offer. If at the scheduled expiration time of the Offer any of the conditions
to the Offer have not been satisfied (unless such condition is waivable by Purchaser or Parent and has been waived), Purchaser will, and
Parent will cause Purchaser to, extend the Offer to permit the satisfaction of all Offer conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The obligation of Purchaser to consummate the Offer
is subject to the satisfaction or waiver of customary conditions, including, among others, (i) there being validly tendered and not validly
withdrawn prior to the expiration of the Offer a number of Shares that, considered together with all other Shares (if any) beneficially
owned by Parent and its affiliates, represent one more Share than 50% of the total number of Shares outstanding at the expiration of the
Offer, (ii) the expiration or termination of the waiting period applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended (the &#8220;<span style="text-decoration: underline">HSR Act</span>&#8221;), (iii) the absence of any law or order
prohibiting the consummation of the Offer or the Merger in any jurisdiction in which Parent or the Company has material business operations
and (iv) other customary conditions set forth in Annex I to the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the consummation of the Offer and subject
to the terms and conditions of the Merger Agreement, Purchaser will merge with and into the Company pursuant to Section 251(h) of the
General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration: underline">DGCL</span>&#8221;), with the Company
being the surviving corporation (the &#8220;<span style="text-decoration: underline">Merger</span>&#8221;). At the effective time of the
Merger, each Share (other than (i) Shares held by the Company (or held in the Company&#8217;s treasury), (ii) Shares held by Parent, Purchaser,
or any other direct or indirect wholly owned subsidiary of Parent, (iii) Shares irrevocably accepted for purchase pursuant to the Offer
and (iv) Shares held by stockholders who have properly exercised and perfected their demands for appraisal of such Shares in accordance
with the DGCL and have neither withdrawn nor lost such rights prior to the effective time of the Merger) will be converted into the right
to receive an amount in cash equal to the Offer Price, without interest and subject to any required withholding of taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Merger Agreement includes customary representations,
warranties and covenants of the Company, Parent and Purchaser.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has agreed to customary &#8220;no-shop&#8221;
restrictions on its ability to solicit alternative acquisition proposals from third parties and engage in discussions or negotiations
with third parties regarding alternative acquisition proposals. Notwithstanding these restrictions, the Company may under certain circumstances
provide information to and participate in discussions or negotiations with third parties with respect to a bona fide written alternative
acquisition proposal that the board of directors of the Company has determined constitutes or would reasonably be expected to result in
a Superior Offer (as defined in the Merger Agreement), if failing to do so would be inconsistent with the board&#8217;s fiduciary duties
under applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Merger Agreement also provides that, in connection
with the termination of the Merger Agreement under specified circumstances, including termination by the Company to accept and enter into
an agreement with respect to a Superior Offer (as defined in the Merger Agreement), the Company will pay Parent a termination fee of $151,600,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the Merger Agreement
and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger
Agreement, which is filed as Exhibit 2.1 hereto and which is incorporated herein by reference. The Merger Agreement has been filed to
provide information to investors regarding its terms. It is not intended to provide any other factual information about Parent, Purchaser
or the Company, their respective businesses, or the actual conduct of their respective businesses during the period prior to the consummation
of the Offer, the Merger or the other transactions contemplated by the Merger Agreement. The Merger Agreement and this summary should
not be relied upon as disclosure about Parent or the Company. None of the Company&#8217;s stockholders or any other third parties should
rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or
conditions of Parent, Purchaser, the Company or any of their respective subsidiaries or affiliates. The Merger Agreement contains representations
and warranties that are the product of negotiations among the parties thereto and that the parties made to, and solely for the benefit
of, each other as of specified dates. The assertions embodied in those representations and warranties are subject to qualifications and
limitations agreed to by the respective parties and are also qualified in important part by confidential disclosure schedules delivered
in connection with the signing of the Merger Agreement. The representations and warranties (i) may have been made for the purpose of allocating
contractual risk between the parties to the Merger Agreement instead of establishing these matters as facts, and may be subject to standards
of materiality applicable to the contracting parties that differ from what an investor may view as material and (ii) may have been made
only as of the date of the Merger Agreement or as of another date or dates as may be specified in the Merger Agreement, and information
concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent
information may or may not be fully reflected in the public disclosures of the Company or Parent, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 12%; font-size: 10pt"><b>Item 8.01.</b></td>
    <td style="font-size: 10pt; width: 88%"><b>Other Events.</b></td></tr>
  </table>

<p style="margin: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 12, 2024, Parent and the Company issued
a joint press release announcing their entry into the Merger Agreement, a copy of which is attached as Exhibit 99.1 to this Current Report
on Form 8-K and incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><b>Forward-Looking Statements
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form 8-K contains forward-looking statements
related to Gilead Sciences, Inc. (&#8220;<span style="text-decoration: underline">Gilead</span>&#8221;), CymaBay Therapeutics, Inc. (&#8220;<span style="text-decoration: underline">CymaBay</span>&#8221;)
and the acquisition of CymaBay by Gilead that are subject to risks, uncertainties and other factors. All statements other than statements
of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief
or current expectation of Gilead and CymaBay and members of their respective senior management teams. Forward-looking statements include,
without limitation, statements regarding the transaction and related matters, prospective performance and opportunities, post-closing
operations and the outlook for the companies&#8217; businesses, including, without limitation, the ability of Gilead to advance CymaBay&#8217;s
product pipeline and successfully commercialize seladelpar&#894; the possibility of unfavorable results from clinical trials; regulatory
applications and related timelines; filings and approvals relating to the transaction&#894; the expected timing of the completion of
the transaction&#894; the ability to complete the transaction considering the various closing conditions&#894; difficulties or unanticipated
expenses in connection with integrating the companies&#894; and any assumptions underlying any of the foregoing. Investors are cautioned
that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned
not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated
due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated
by forward-looking statements include: uncertainties as to the timing of the tender offer and merger&#894; uncertainties as to how many
of CymaBay&#8217;s stockholders will tender their stock in the offer&#894; the possibility that competing offers will be made&#894; the
possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity
may prohibit, delay or refuse to grant approval for the consummation of the transaction&#894; the effects of the transaction on relationships
with employees, other business partners or governmental entities&#894; the difficulty of predicting the timing or outcome of regulatory
approvals or actions, if any; the impact of competitive products and pricing&#894; other business effects, including the effects of industry,
economic or political conditions outside of the companies&#8217; control&#894; transaction costs&#894; actual or contingent liabilities;
adverse impacts on business, operating results or financial condition in the future due to pandemics, epidemics or outbreaks&#894; and
other risks and uncertainties detailed from time to time in the companies&#8217; periodic reports filed with the U.S. Securities and
Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;), including current reports on Form 8-K, quarterly
reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by CymaBay and the Schedule TO and related
tender offer documents to be filed by Gilead and Pacific Merger Sub, Inc., a wholly owned subsidiary of Gilead. All forward-looking statements
are based on information currently available to Gilead and CymaBay, and Gilead and CymaBay assume no obligation and disclaim any intent
to update any such forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><b>Additional Information
and Where to Find It</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The tender offer described in this Current Report Form 8-K has not
yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer
to sell securities of CymaBay, nor is it a substitute for any tender offer materials that Gilead, Pacific Merger Sub, Inc. or CymaBay
will file with the SEC. A solicitation and an offer to buy securities of CymaBay will be made only pursuant to an offer to purchase and
related materials that Gilead intends to file with the SEC. At the time the tender offer is commenced, Gilead will file a Tender Offer
Statement on Schedule TO with the SEC, and CymaBay will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with
respect to the tender offer. CYMABAY&#8217;S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING
AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT
ON SCHEDULE 14D-9 BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT
TO THE TENDER OFFER. The Offer to Purchase, the related letter of transmittal and certain other tender offer documents, as well as the
Solicitation/Recommendation Statement on Schedule 14D-9, will be sent to all stockholders of CymaBay at no expense to them. The Tender
Offer Statement on Schedule TO, the Solicitation/Recommendation Statement on Schedule 14D-9 and other related documents will be made
available for free at the SEC&#8217;s web site at <span style="text-decoration: underline; color: Blue">www.sec.gov</span>. Additional
copies may be obtained for free by contacting Gilead or CymaBay. Free copies of these materials and certain other offering documents
will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations,
by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which
will be named in the Tender Offer Statement on Schedule TO. Investors and security holders of CymaBay may also obtain, free of charge,
the Solicitation/Recommendation Statement on Schedule 14D-9 and other related documents that CymaBay has filed with or furnished to the
SEC under the &#8220;Investors &amp; Media&#8221; section of CymaBay&#8217;s website at <span style="text-decoration: underline; color: Blue">www.cymabay.com/investors-media</span><span style="text-decoration: underline">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the Offer to Purchase, the related Letter of Transmittal
and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Gilead and CymaBay file annual, quarterly
and current reports, proxy statements and other information with the SEC. Gilead&#8217;s and CymaBay&#8217;s filings with the SEC are
also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at <span style="text-decoration: underline; color: Blue">www.sec.gov</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 12%; font-size: 10pt"><b>Item 9.01.</b></td>
    <td style="font-size: 10pt; width: 88%"><b>Financial Statements and Exhibits</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 7%; font-size: 10pt">(d)</td>
    <td style="padding-left: 20.4pt; font-size: 10pt; text-align: justify; text-indent: -20.4pt">Exhibits</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibit 99.1 is furnished pursuant to this Item 9.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; padding-top: 1pt; padding-bottom: 1pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number&#160;</p></td>
    <td style="padding-top: 1pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-top: 1pt; padding-bottom: 1pt">Description</td></tr>
  <tr>
    <td style="padding-top: 1pt; vertical-align: top; padding-bottom: 1pt"><a href="dp206638_ex0201.htm">2.1*</a></td>
    <td style="padding-top: 1pt; vertical-align: bottom; padding-bottom: 1pt">&#160;</td>
    <td style="padding-top: 1pt; vertical-align: bottom; padding-bottom: 1pt"><a href="dp206638_ex0201.htm">Agreement and Plan of Merger, dated February 11, 2024, among CymaBay
Therapeutics, Inc., Gilead Sciences, Inc. and Pacific Merger Sub, Inc.</a></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-top: 1pt; padding-bottom: 1pt"><a href="dp206638_ex9901.htm">99.1</a></td>
    <td style="padding-top: 1pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-top: 1pt; padding-bottom: 1pt"><a href="dp206638_ex9901.htm">Joint Press Release, dated February 12, 2024.</a></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-top: 1pt; padding-bottom: 1pt">104</td>
    <td style="padding-top: 1pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-top: 1pt; padding-bottom: 1pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Schedules omitted pursuant to Item 601(a)(5) of Regulation S-K. Gilead
agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">GILEAD SCIENCES, INC.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>By:</td>
    <td colspan="2" style="border-bottom: black 1pt solid">/s/ ANDREW DICKINSON</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 4%">Name:</td>
    <td style="width: 41%">Andrew Dickinson</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: February 12, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

</body>
</html>
